FDA Permits Marketing of Stimulation Device for Treatment of Obsessive Compulsive Disorder – Drug for nerve pain boosts high for opioid abusers.

16511-pharmacy-board-standard-041216Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Permits Marketing of Stimulation Device for Treatment of Obsessive Compulsive Disorder – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA have given approval for marketing Brainsway’s Deep Transcranial Magnetic Stimulation (TMS) System. The device is utulized for treatment of obsessive compulsive disorder (OCD).

“Transcranial magnetic stimulation has shown its potential to help patients suffering from depression and headaches,” said Carlos Peña, PhD, MS, director of the Division of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health, in a prepared statement. “Patients with OCD who have not responded to traditional treatments now have another option.”

TMS is a procedure that utilizes magnetic fields to stimulate nerve cells in the brain. The FDA permitted marketing of TMS as a treatment for major depression in 2008, and the agency expanded the use to include TMS for treating pain associated with certain migraine headaches in 2013.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.